Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC3 | O15379 | 11/20 | 1.00 |
| ▸ | HDAC4 | P56524 | 11/20 | 1.00 |
| ▸ | HDAC1 | Q13547 | 11/20 | 1.00 |
| ▸ | HDAC7 | Q8WUI4 | 11/20 | 1.00 |
| ▸ | HDAC2 | Q92769 | 11/20 | 1.00 |
| ▸ | HDAC10 | Q969S8 | 11/20 | 1.00 |
| ▸ | HDAC11 | Q96DB2 | 11/20 | 1.00 |
| ▸ | HDAC8 | Q9BY41 | 11/20 | 1.00 |
| ▸ | HDAC6 | Q9UBN7 | 11/20 | 1.00 |
| ▸ | HDAC9 | Q9UKV0 | 11/20 | 1.00 |
| ▸ | HDAC5 | Q9UQL6 | 11/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.63 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.63 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.63 |
| ▸ | LMNA | P02545 | 2/20 | 0.59 |
| ▸ | USP2 | O75604 | 1/20 | 0.59 |
| ▸ | TSHR | P16473 | 1/20 | 0.59 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.59 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.59 |
| ▸ | ABL1 | P00519 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| R-306465 SCHEMBL31237823 | 1.00 | HDAC3 (1.00) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL10225878 | 0.96 | HDAC3 (0.92) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL8250702 | 0.91 | HDAC3 (0.83) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL12341261 | 0.90 | HDAC6 (0.82) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL12341260 | 0.90 | HDAC6 (0.82) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL8251579 | 0.88 | HDAC3 (1.00) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL335493 | 0.88 | HDAC3 (0.78) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL1618952 | 0.88 | HDAC1 (0.78) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL8222113 | 0.87 | HDAC1 (0.77) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL1617712 | 0.87 | HDAC1 (0.76) | HDAC3HDAC4HDAC1HDAC7HDAC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 443 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260007676-A1 | HDAC INHIBITORS FOR USE WITH NK CELL BASED THERAPIES | VIRACTA THERAPEUTICS INC (US) | 2026-01-08 | — | — | US | claimed |
| WO-2025151443-A1 | ENDOXIFEN FOR TREATMENT OF RARE CANCERS | ATOSSA THERAPEUTICS, INC. (US) | 2025-07-17 | — | — | WO | claimed |
| US-20250161243-A1 | MEF2 TRANSCRIPTIONAL ACTIVATORS TO TREAT NEUROLOGIC CONDITIONS | THE SCRIPPS RESEARCH INSTITUTE | 2025-05-22 | — | — | US | claimed |
| EP-4508211-A2 | THERAPEUTIC APPLICATIONS OF CRISPR TYPE V SYSTEMS | Caribou Biosciences, Inc. (US) | 2025-02-19 | — | — | EP | claimed |
| US-12187698-B2 | Crystalline forms of C21H22Cl2N4O2 | BIOMED VALLEY DISCOVERIES, INC. (US) | 2025-01-07 | — | — | US | claimed |
| US-20240390375-A1 | METHODS AND COMPOSITIONS FOR TREATING VIRAL OR VIRALLY-INDUCED CONDITIONS | Viracta Subsidiary, Inc. (US) | 2024-11-28 | — | — | US | claimed |
| CN-118974253-A | Therapeutic application of CRISPR V-type system | 卡里布生物科学公司 | 2024-11-15 | — | — | CN | claimed |
| WO-2024192348-A2 | METHODS OF TREATING HPV IN HIV-INFECTED PATIENTS | OHIO STATE INNOVATION FOUNDATION (US) | 2024-09-19 | — | — | WO | claimed |
| WO-2023201270-A2 | THERAPEUTIC APPLICATIONS OF CRISPR TYPE V SYSTEMS | CARIBOU BIOSCIENCES, INC. (US) | 2023-10-19 | — | — | WO | claimed |
| US-20220324832-A1 | CRYSTALLINE FORMS OF C21H22Cl2N4O2 | VERTEX PHARMACEUTICALS INCORPORATED | 2022-10-13 | — | — | US | claimed |
| CN-114948963-A | Protein kinase inhibitor benzolactam compounds | 大冢制药株式会社 | 2022-08-30 | — | — | CN | claimed |
| US-20220249477-A1 | METHODS AND COMPOSITIONS FOR TREATING VIRAL OR VIRALLY-INDUCED CONDITIONS | VIRACTA THERAPEUTICS, INC. (US) | 2022-08-11 | — | — | US | claimed |
| US-9877962-B2 | Piperazinyl derivatives for the treatment of cancer | Pitty, Marc Henry (FR) | 2018-01-30 | — | — | US | claimed |
| US-20260124214-A1 | HETEROCYCLIC COMPOUNDS FOR USE IN THE TREATMENT OF CANCER | ARTIOS PHARMA LIMITED (GB) | 2026-05-07 | — | — | US | disclosed |
| US-20260102394-A1 | PYRAZOLO[3,4-B]PYRAZINE SHP2 PHOSPHATASE INHIBITORS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2026-04-16 | — | — | US | disclosed |
| US-20260078414-A1 | Materials and Methods for Treatment of Pain Related Disorders | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2026-03-19 | — | — | US | disclosed |
| US-20070142393-A1 | SULFONYL-DERIVATIVES AS NOVEL INHIBITORS OF HISTONE DEACETYLASE | EMELEN KRISTOF V | 2007-06-21 | — | — | US | disclosed |
| US-20070142393-A1 | SULFONYL-DERIVATIVES AS NOVEL INHIBITORS OF HISTONE DEACETYLASE | EMELEN KRISTOF V | 2007-06-21 | — | — | US | disclosed |
| WO-2007049262-A1 | Methods and compositions for the promotion of neuronal growth and the treatment of asociality and affective disorders | BERAND LIMITED (IE) | 2007-05-03 | — | — | WO | disclosed |
| US-7205304-B2 | medicine to inhibit proliferative conditions, such as cancer and psoriasis | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-04-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220324832-A1 | CRYSTALLINE FORMS OF C21H22Cl2N4O2 | CYP2F1, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, CA4 | HDAC3 2519/4885HDAC4 1315/4885HDAC1 908/4885 |
| US-20260124214-A1 | HETEROCYCLIC COMPOUNDS FOR USE IN THE TREATMENT OF CANCER | CBR1, NR3C1, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 | HDAC3 52/4885HDAC4 1044/4885HDAC1 372/4885 |
| US-20260007676-A1 | HDAC INHIBITORS FOR USE WITH NK CELL BASED THERAPIES | HDAC9, HDAC4, HDAC5 | HDAC3 5/4885HDAC4 2/4885HDAC1 11/4885 |
| US-12187698-B2 | Crystalline forms of C21H22Cl2N4O2 | CYP2F1, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, CA4 | HDAC3 2519/4885HDAC4 1315/4885HDAC1 908/4885 |
| US-20260102394-A1 | PYRAZOLO[3,4-B]PYRAZINE SHP2 PHOSPHATASE INHIBITORS | PTPN5, PTPN1, PTPN3 | HDAC3 478/4885HDAC4 736/4885HDAC1 408/4885 |
| US-20260078414-A1 | Materials and Methods for Treatment of Pain Related Disorders | SCN9A, SCN7A, SCN8A | HDAC3 3492/4885HDAC4 3661/4885HDAC1 4301/4885 |
| US-20070142393-A1 | SULFONYL-DERIVATIVES AS NOVEL INHIBITORS OF HISTONE DEACETYLASE | HDAC3, HDAC1, HDAC11 | HDAC3 1/4885HDAC4 6/4885HDAC1 2/4885 |
| US-20250161243-A1 | MEF2 TRANSCRIPTIONAL ACTIVATORS TO TREAT NEUROLOGIC CONDITIONS | MEF2D, TEAD2, TEAD1 | HDAC3 842/4885HDAC4 81/4885HDAC1 186/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.